Granted Patent
B2
US 12,459,970 · App. 17/592,870 · Granted Nov 4, 2025
Progesterone analogs and uses related thereto
Inventors:
David B. Guthrie (Avondale Estates, GA); Mark A. Lockwood (Johns Creek, GA); Dennis C. Liotta (Atlanta, GA); Michael G. Natchus (Alpharetta, GA); Donald G. Stein (Atlanta, GA); Iqbal Sayeed (Atlanta, GA)
Assignee:
Emory University
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke.
Claims (28)
1 . A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2 . A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
3 . The pharmaceutical composition of claim 2 , further comprising a second active therapeutic agent.
4 . A method for reducing symptoms or delaying progression of inflammation, stroke, or traumatic brain injury in a subject, comprising:
administering to the subject a pharmaceutical composition comprising a compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
5 . The method of claim 4 , wherein the pharmaceutical composition is administered to a subject after a traumatic brain injury.
6 . The method of claim 5 , wherein the pharmaceutical composition is administered to the subject within 24 hours after the traumatic brain injury.
7 . The method of claim 5 , wherein the traumatic brain injury results from a skull fracture, a parenchymal injury, or a vascular injury.
8 . The method of claim 4 , wherein the pharmaceutical composition is administered to a subject after a stroke.
9 . The method of claim 8 , wherein the pharmaceutical composition is administered to the subject within 24 hours after the stroke.
10 . The method of claim 8 , wherein the stroke is an ischemic stroke.
11 . The method of claim 8 , wherein the stroke is a hemorrhagic stroke.
12 . The method of claim 4 , further comprising administering a second active therapeutic agent.
13 . The method of claim 12 , wherein the second active therapeutic agent is an anti-inflammatory agent.
14 . A method for reducing the symptoms or delaying progression of a neurodegenerative disease in a subject, comprising:
administering to the subject a pharmaceutical composition comprising a compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
15 . The method of claim 14 , wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, dementia, extrapyramidal and movement disorders, motor neurone disease, systemic atrophies, Tay-Sachs disease, ataxia telangiectasia, Batten disease, corticobasal degeneration, Creutzfeldt-Jakob disease, fatal familial insomnia, infantile Refsum disease, lyme disease, Machado-Joseph disease, multiple system atrophy, neuroacanthocytosis, Niemann-Pick disease, refsum disease, Sandhoff disease, Shy-Drager syndrome, spinocerebellar ataxia, tabes dorsalis, toxic encephalopathy, or Wobbly hedgehog syndrome.
16 . The method of claim 15 , wherein the neurodegenerative disease is amyotrophic lateral sclerosis.
17 . The method of claim 15 , wherein the neurodegenerative disease is Parkinson's disease.
18 . A method for supporting a hormonal condition in a subject, comprising:
administering to the subject a pharmaceutical composition comprising a compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
19 . The method of claim 18 , wherein the hormonal condition is pregnancy.
20 . The method of claim 19 , wherein the pregnancy is a result of in vitro fertilization.
21 . The method of claim 18 , wherein the hormonal condition is persistent anovulatory bleeding, inadequate progesterone production, or endometrial hyperplasia.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 5, 2022
From: GUTHRIE, DAVID B.; LOCKWOOD, MARK A.; NATCHUS, MICHAEL G.; LIOTTA, DENNIS C.; STEIN, DONALD G.; SAYEED, IQBAL
To: EMORY UNIVERSITY
Reel/Frame 060728/0352 →
Continuity (5)
Provisional Application
61599079
· Feb 15, 2012
References Cited (138)
US 6245757B1
· Chopp et al.
· 2001
[cited by applicant]
US 6673908B1
· Stanton, Jr.
· 2004
[cited by examiner]
US 9527881B2
· Macnevin et al.
· 2016
[cited by applicant]
US 9802978B2
· Guthrie
· 2017
[cited by examiner]
US 20090221544A1
· Stein et al.
· 2009
[cited by applicant]
US 20090325920A1
· Hoffman et al.
· 2009
[cited by applicant]
US 20110306579A1
· Stein
· 2011
[cited by applicant]
US 20120245133A1
· Hoffman et al.
· 2012
[cited by applicant]
US 20140349984A1
· Hoffman et al.
· 2014
[cited by applicant]
WO 0230409
· 2002
[cited by applicant]
WO 2006102596
· 2006
[cited by applicant]
WO 2006102644
· 2006
[cited by applicant]
WO 2008142720
· 2008
[cited by applicant]
WO 2009097578
· 2009
[cited by applicant]
WO 2009108804
· 2009
[cited by applicant]
WO 2010020889
· 2010
[cited by applicant]
Clevland Clinic “Parkinson's Disease” 2024.
[cited by examiner]
Clevland Clinic Amyotrophic Lateral Sclerosis 2024.
[cited by examiner]
Cleavland Clinic “Ataxia-Telangiectasia” 2024.
[cited by examiner]
Cleavland Clinic “Batten Disease” 2024.
[cited by examiner]
Clevalnd Clinic “Fatal Familial Insomnia” 2024.
[cited by examiner]
Cleavland Clinic “Niemann-Pick Disease (NP)” 2024.
[cited by examiner]
Cleavland Cllinic “Sandhoff Disease” 2024.
[cited by examiner]
Cleavland Clinic “Spinocerebellar Ataxia”( Machado-Joseph disease) 2024.
[cited by examiner]
Cleavland Clinic “Movement Disorders” 2024.
[cited by examiner]
Cleavland Clinic “Encephalopathy” 2024.
[cited by examiner]
NHS “Alzheimer's Disease” 2024.
[cited by examiner]
NHS “Huntington's disease” 2024.
[cited by examiner]
NHS “Multiple sclerosis” 2024.
[cited by examiner]
MiniPill (progestin-only birth control pill) 2024.
[cited by examiner]
“No reputable evidence for progesterone use in abortion reversal, say medical organizations” 2022.
[cited by examiner]
NHS “Is there a cure for dementia?” 2024 (Year: 2024).
[cited by examiner]
NHS “Motor neurone disease” 2021 (Year: 2021).
[cited by examiner]
NHS “Multiple system atrophy” 2020 (Year: 2020).
[cited by examiner]
NHS “Overview-Corticobasal degeneration” 2022 (Year: 2022).
[cited by examiner]
NHS “Tay-Sachs disease” 2021 (Year: 2021).
[cited by examiner]
NHS “Treatment-Creutzfeldt-Jakob disease” 2021 (Year: 2021).
[cited by examiner]
Orphanet “Infantile Refsum disease” 2021 (Year: 2021).
[cited by examiner]
NIH “Neuroacanthocytosis” 2024 (Year: 2024).
[cited by examiner]
NIH “Tabes Dorsalis” 2024 (Year: 2024).
[cited by examiner]
VCA Animal Hospitals “Wobbly Hedgehog Syndrome—VCA Animal Hospitals” 2022 (Year: 2022).
[cited by examiner]
U.S. Appl. No. 14/932,231, Final Office Action mailed on Apr. 21, 2017, 14 pages.
[cited by applicant]
U.S. Appl. No. 14/932,231, Final Office Action mailed on Jun. 26, 2018, 15 pages.
[cited by applicant]
U.S. Appl. No. 14/932,231, Non-Final Office Action mailed on Aug. 24, 2016, 17 pages.
[cited by applicant]
U.S. Appl. No. 14/932,231, Non-Final Office Action mailed on Nov. 1, 2017, 25 pages.
[cited by applicant]
U.S. Appl. No. 14/932,231, Notice of Allowance mailed on Feb. 21, 2019, 9 pages.
[cited by applicant]
U.S. Appl. No. 14/932,231, Restriction Requirement mailed on Aug. 10, 2017, 7 pages.
[cited by applicant]
U.S. Appl. No. 16/421,255, Final Office Action mailed on Jul. 20, 2021, 14 pages.
[cited by applicant]
U.S. Appl. No. 16/421,255, Non-Final Office Action mailed on Nov. 30, 2020, 13 pages.
[cited by applicant]
U.S. Appl. No. 16/421,255, Notice of Allowance mailed on Nov. 8, 2021, 10 pages.
[cited by applicant]
Alexis et al., Nonocclusive Common Carotid Artery Thrombosis in the Rat Results in Reversible Sensorimotor and Cognitive Behavioral Deficits, Stroke, vol. 26, 1995, pp. 2336-2346.
[cited by applicant]
Arvin et al., The Role of Inflammation and Cytokines in Brain Injury, Neuroscience & Biobehavioral Reviews Autumn, vol. 20, No. 3, 1996, pp. 445-452.
[cited by applicant]
Atif et al., Progesterone in the Treatment of Neonatal Arterial Ischemic Stroke and Acute Seizures: Role of Bdnf/trkb Signaling, Neuropharmacology, vol. 107, 2016, pp. 317-328.
[cited by applicant]
Barbakadze et al., Chemical Modification of Oximes With N-protected Amino Acids, Tetrahedron, vol. 70, 2014, pp. 7181-7184.
[cited by applicant]
Barone et al., Inflammatory Mediators and Stroke: New Opportunities for Novel Therapeutics, Journal of Cerebral Blood Flow and Metabolism, vol. 19, Aug. 1999, pp. 819-834.
[cited by applicant]
Baulieu, Adv Biochem Psychopharmacol, vol. 47, 1992, pp. 1-16.
[cited by applicant]
Baulieu, Neurosteroids: Of the Nervous System, by the Nervous System, for the Nervous System, Recent Progress in Hormone Research, vol. 52, 1997, pp. 1-32.
[cited by applicant]
Beaumont et al., The Impact-Acceleration Model of Head Injury: Injury Severity Predicts Motor and Cognitive Performance after Trauma, Neurological Research, vol. 21, 1999, pp. 742-754.
[cited by applicant]
Becker et al., Neuroanatomical Bases of Spatial Memory, Brain Research, vol. 200, Nov. 1980, pp. 307-320.
[cited by applicant]
Bederson et al., Rat Middle Cerebral Artery Occlusion: Evaluation of the Model and Development of a Neurologic Examination, Stroke, vol. 17, No. 3, May-Jun. 1986, pp. 472-476.
[cited by applicant]
Betz et al., Effect of Steroids on Edema and Sodium Uptake of the Brain During Focal Ischemia in Rats, Stroke, vol. 21, No. 8, Aug. 1990, pp. 1199-1204.
[cited by applicant]
Chao et al., Steroid Sex Hormones and Macrophage Function: Modulation of Reactive Oxygen Intermediates and Nitrite Release, American Journal of Reproductive Immunology, vol. 32, Aug. 1994, pp. 43-52.
[cited by applicant]
Check et al., Lymphocyte Immunotherapy (LI) Increases Serum Levels of Progesterone Induced Blocking Factor (PIBF), American Journal of Reproductive Immunology, vol. 37, Issue 1, 1997, pp. 17-20.
[cited by applicant]
Corey et al., Reaction of Oxime O-Acetates with Chromous Acetate. A Method for the Conversion of Ketoximes to Ketones Under Mild Conditions, Journal of the American Chemical Society, vol. 92, No. 17, May 11, 1970, pp. 5…
[cited by applicant]
Del Zoppo et al., Advances in the Vascular Pathophysiology of Ischemic Stroke, Thrombosis Research, vol. 98, Issue 3, May 1, 2000, pp. 73-81.
[cited by applicant]
Deryck et al., Brain Research, vol. 573, 1992, pp. 44-60.
[cited by applicant]
Djebaili et al., Allopregnanolone and Progesterone Decrease Cell Death and Cognitive Deficits After a Contusion of the Rat Pre-Frontal Cortex, Neuroscience, vol. 123, Issue 2, Feb. 2004, pp. 349-359.
[cited by applicant]
Djebaili et al., The Neurosteroids Progesterone and Allopregnanolone Reduce Cell Death, Gliosis, and Functional Deficits after Traumatic Brain Injury in Rats, Journal of Neurotrauma, vol. 22, No. 1, Jan. 21, 2005, pp. 1…
[cited by applicant]
Ganter et al., Growth Control of Cultured Microglia, Journal of Neuroscience Research, vol. 33, Issue 2, Oct. 1992, pp. 218-230.
[cited by applicant]
Garcia-Estrada et al., Dehydroepiandrosterone, Pregnenolone and Sexsteroids Down-Regulate Reactive Astroglia in the Male Ratbrain after a Penetrating Brain Injury, International Journal of Developmental Neuroscience, vo…
[cited by applicant]
Garcia-Estrada et al., Gonadal Hormones Down-Regulate Reactive Gliosis and Astrocyte Proliferation after a Penetrating Brain Injury, Brain Research, vol. 628, Issues 1-2, Nov. 19, 1993, pp. 271-278.
[cited by applicant]
Goodman et al., Estrogens Attenuate and Corticosterone Exacerbates Excitotoxicity, Oxidative Injury, and Amyloid/3-Peptide Toxicity in Hippocampal Neurons, Journal of Neurochemistry, vol. 66, May 1996, pp. 1836-1844.
[cited by applicant]
Grossman et al., Effects of Progesterone on the Inflammatory Response to Brain Injury in the Rat, Brain Research, vol. 1008, Issue 1, May 15, 2004, pp. 29-39.
[cited by applicant]
Guthrie et al., Water-soluble Progesterone Analogues Are Effective, Injectable Treatments in Animal Models of Traumatic Brain Injury, ACS Medicinal Chemistry Letters, vol. 3, No. 5, May 10, 2012, pp. 362-366.
[cited by applicant]
Hartmann et al., Synthesis and Evaluation of Novel Steroidal Oxime Inhibitors of P450 17 (17α-Hydroxylase/C17-20-Lyase) and 5α-Reductase Types 1 and 2Journal of Medicinal Chemistry, Journal of Medicinal Chemistry, vol. …
[cited by applicant]
Hayashi et al., Novel Non-Peptide Nociceptin/Orphanin FQ Receptor Agonist, 1-[1-(1-Methylcyclooctyl)-4-Piperidinyl]-2-[(3R)-3-Piperidinyl]-1H-Benzimidazole: Design, Synthesis, and Structure-Activity Relationship of Oral…
[cited by applicant]
Hayes et al., Neurotransmitter Mediated Mechanisms of Traumatic Brain Injury: Acetylcholine and Excitatory Amino Acids, Journal of Neurotrauma, vol. 9, Supplement 1, Apr. 1992, pp. S173-S187.
[cited by applicant]
He et al., Allopregnanolone, a Progesterone Metabolite, Enhances Behavioral Recovery and Decreases Neuronal Loss after Traumatic Brain Injury, Restorative Neurology and Neuroscience, vol. 22, No. 1, Jan. 1, 2004, pp. 19…
[cited by applicant]
He et al., Progesterone and Allopregnanolone Reduce Inflammatory Cytokines after Traumatic Brain Injury, Experimental Neurology, vol. 189, No. 2, Jun. 7, 2004, pp. 404-412.
[cited by applicant]
Hoffman et al., Allopregnanolone Promotes Functional Recovery from TBI by Reducing Cerebral Edema and Neuronal Death, Academy of Emergency Medicine, vol. 8, 2001, pp. 496-497.
[cited by applicant]
Hoffman et al., Bilateral Frontal Cortical Contusion in Rats: Behavioral and Anatomie Consequences, Journal of Neurotrauma, vol. 11, No. 4, Aug. 1994, pp. 417-431.
[cited by applicant]
Holmin et al., Intracerebral Inflammatory Response to Experimental Brain Contusion, Acta Neurochirurgica, vol. 132, Mar. 1995, pp. 110-119.
[cited by applicant]
Jiang et al., Progesterone is Neuroprotective after Transient Middle Cerebral Artery Occlusion in Male Rats, Brain Research, vol. 735, Issue 1, Sep. 30, 1996, pp. 101-107.
[cited by applicant]
Kelly et al., The Inhibition of Synthesis of a β-Chemokine, Monocyte Chemotactic Protein-1 (MCP-1) by Progesterone, Biochemical and Biophysical Research Communications, vol. 239, Issue 2, Oct. 20, 1997, pp. 557-561.
[cited by applicant]
Kim et al., Synthesis of Pregnane Derivatives, Their Cytotoxicity on LNCap and PC-3 Cells, and Screening on 5α-Reductase Inhibitory Activity, Molecules, vol. 14, 2009, pp. 4655-4668.
[cited by applicant]
Kline et al., Methylphenidate Treatment Following Ablation-induced Hemiplegia in Rat: Experience During Drug Action Alters Effects on Recovery of Function, Pharmacology Biochemistry and Behavior, vol. 48, Jul. 1994, pp.…
[cited by applicant]
Lambert et al., Neurosteroids and GABAA, Receptor Function, Trends in Pharmacological Sciences, vol. 16, Issue 9, Sep. 1995, pp. 295-303.
[cited by applicant]
Lindner et al., Dissociable Long-term Cognitive Deficits After Frontal Versus Sensorimotor Cortical Contusions, Journal of Neurotrauma, vol. 15, No. 3, Mar. 1998, pp. 199-216.
[cited by applicant]
Lyeth et al., Cholinergic and opioid medication of traumatic brain injury, Journal of Neurotrauma, vol. 9, No. 2, 1992, pp. S463-S474.
[cited by applicant]
MacNevin et al., Development and Screening of Water-Soluble Analogues of Progesterone and Allopregnanolone in Models of Brain Injury, Journal of Medicinal Chemistry, vol. 52, No. 19, Oct. 8, 2009, pp. 6012-6023.
[cited by applicant]
Markgraf et al., Sensorimotor and Cognitive Consequences of Middle Cerebral Artery Occlusion in Rats, Brain Research, vol. 575, No. 2, Mar. 1992, pp. 238-246.
[cited by applicant]
Mattson et al., Cellular Signaling Roles of TGFβ, TNFα and βAPP in Brain Injury Responses and Alzheimer's Disease, Brain Research Reviews, vol. 23, Issues 1-2, Feb. 1997, pp. 47-61.
[cited by applicant]
Maurice et al., Journal of Neuroscience Research, 1996.
[cited by applicant]
Maurice et al., Sigma1 (01) Receptor Agonists and Neurosteroids Attenuate β25-35-Amyloid Peptide-Induced Amnesia in Mice through a Common Mechanism, Neuroscience, vol. 83, Issue 2, Dec. 31, 1998, pp. 413-428.
[cited by applicant]
Miller et al., Progesterone Inhibits Inducible Nitric Oxide Synthase Gene Expression and Nitric Oxide Production in Murine Macrophages, Journal of Leukocyte Biology, vol. 59, Issue 3, Mar. 1996, pp. 442-450.
[cited by applicant]
Morris, Developments of a Water-Maze Procedure for Studying Spatial Learning in the Rat, Journal of Neuroscience Methods, vol. 11, May 1984, pp. 47-60.
[cited by applicant]
Murphy et al., Progesterone Administration During Reperfusion, but not Preischemia Alone, Reduces Injury in Ovariectomized Rats, Journal of Cerebral Blood Flow & Metabolism, vol. 22, No. 10, Oct. 2002, pp. 1181-1188.
[cited by applicant]
Murphy et al., Progesterone Exacerbates Striatal Stroke Injury in Progesterone-Deficient Female Animals, Stroke, vol. 31, No. 5, May 2000, pp. 1173-1178.
[cited by applicant]
Perera et al., Inflammation Following Stroke, Journal of Clinical Neuroscience, vol. 13, No. 1, Jan. 2006, pp. 1-8.
[cited by applicant]
Pettus et al., Progesterone Treatment Inhibits the Inflammatory Agents that Accompany Traumatic Brain Injury, Brain Research, vol. 1049, No. 1, Jul. 5, 2005, pp. 112-119.
[cited by applicant]
Raivich et al., Signaling Molecules and Neuroglial Activation in the Injured Central Nervous System, The Keio Journal of Medicine, vol. 45, Issue 3, Sep. 1996, pp. 239-247.
[cited by applicant]
Reddy et al., Role of GABA-A and Mitochondrial Diazepam Binding Inhibitor Receptors in the Anti-Stress Activity of Neurosteroids in Mice, Psychopharmacology, vol. 128, Dec. 1, 1996, pp. 280-292.
[cited by applicant]
Reddy et al., Sigma (σ1) Receptor Mediated Antidepressant-Like Effects of Neurosteroids in the Porsolt Forced Swim Test, NeuroReport, vol. 9, Issue 13, Sep. 14, 1998, pp. 3069-3073.
[cited by applicant]
Robert et al., Effects of Female Hormones (17β-Estradiol and Progesterone) on Nitric Oxide Production by Alveolar Macrophages in Rats, Nitric Oxide, vol. 1, Issue 6, Dec. 1997, pp. 453-462.
[cited by applicant]
Roof et al., Progesterone Facilitates Cognitive Recovery and Reduces Secondary Neuronal Loss Caused by Cortical Contusion Injury in Male Rats, Experimental Neurology, vol. 129, Issue 1, Sep. 1994, pp. 64-69.
[cited by applicant]
Roof et al., Progesterone Protects Against Lipid Peroxidation Following Traumatic Brain Injury in Rats, Molecular and Chemical Neuropathology, vol. 31, May 1997, pp. 1-11.
[cited by applicant]
Schallert et al., Posture-Independent Sensorimotor Analysis of Inter-Hemispheric Receptor Asymmetries in Neostriatum, Pharmacology Biochemistry and Behavior, vol. 18, No. 5, May 1983, pp. 753-759.
[cited by applicant]
Soares et al., Inflammatory Leukocytic Recruitment and Diffuse Neuronal Degeneration are Separate Pathological Processes Resulting from Traumatic Brain Injury, The Journal of Neuroscience, vol. 15, No. 12, Dec. 1995, pp…
[cited by applicant]
Stein, Embracing Failure: What the Phase III Progesterone Studies Can Teach about Tbi Clinical Trials, Brain Injury, vol. 9, No. 11, Sep. 19, 2015, pp. 1259-1272.
[cited by applicant]
Stein et al., Goldstein et al.'s Secondary Analysis of Progesterone Clinical Trial for Tbi Can Only Reflect the Same Trial Design Flaws: A Response to Very Early Administration of Progesterone Does Not Improve Neuropsyc…
[cited by applicant]
Stein, The Case for Progesterone, Annals of the New York Academy of Sciences, vol. 1052, No. 1, Jun. 2005, pp. 152-169.
[cited by applicant]
Stroemer et al., Neocortical Neural Sprouting, Synaptogenesis, and Behavioral Recovery After Neocortical Infarction in Rats, Stroke, vol. 26, Issue 11, Nov. 1995, pp. 2135-2144.
[cited by applicant]
Subramanian et al., Gestation Confers Temporary Resistance to Peroxidation in the Maternal Rat Brain, Neuroscience Letters, vol. 155, Issue 2, Jun. 11, 1993, pp. 151-154.
[cited by applicant]
Szekeres-Bartho et al., The Antiabortive Effect of Progesterone-Induced Blocking Factor in Mice is Manifested by Modulating NK Activity, Cellular Immunology, vol. 177, Issue 2, May 1, 1997, pp. 194-199.
[cited by applicant]
Szekeres-Bartho et al., The Immunological Pregnancy Protective Effect of Progesterone is Manifested via Controlling Cytokine Production, American Journal of Reproductive Immunology, vol. 35, No. 4, Apr. 1996, pp. 348-35…
[cited by applicant]
Vasil'Tsov et al., First Example of Construction of a Pyrrole Ring Bonded to a Steroid System by the Trofimov Reaction, Chemistry of Heterocyclic Compounds, vol. 37, No. 12, Dec. 2001, pp. 1488-1492.
[cited by applicant]
Vaudano et al., The Effects of a Lesion or a Peripheral Nerve Graft on GAP-43 Upregulation in the Adult Rat Brain: An in-Situ Hybridization and Immunocytochemical Study, The Journal of Neuroscience, vol. 15, No. 5, May …
[cited by applicant]
Vedder et al., Estrogen Hormones Reduce Lipid Peroxidation in Cells and Tissues of the Central Nervous System, Journal of Neurochemistry, vol. 72, Issue 6, Jun. 1999, pp. 2531-2538.
[cited by applicant]
Wali et al., Evaluating the Neurotherapeutic Potential of a Water-Soluble Progesterone Analog after Traumatic Brain Injury in Rats, Neuropharmacology, vol. 109, 2016, pp. 148-158.
[cited by applicant]
Webster et al., Progesterone Treatment Reduces Neuroinflammation, Oxidative Stress and Brain Damage and Improves Long-Term Outcomes in a Rat Model of Repeated Mild Traumatic Brain Injury, Journal of Neuroinflammation, v…
[cited by applicant]
Wright et al., ProTECT: A Randomized Clinical Trial of Progesterone for Acute Traumatic Brain Injury, Annals of Emergency Medicine, vol. 49, Issue 4, Available Online at: DOI: https://doi.org/10.1016/j.annemergmed.2006.…
[cited by applicant]
Wright et al., Serum Progesterone Levels Correlate with Decreased Cerebral Edema after Traumatic Brain Injury in Male Rats, Journal of Neurotrauma, vol. 18, No. 9, Sep. 2001, pp. 901-909.
[cited by applicant]
Wright et al., Very Early Administration of Progesterone for Acute Traumatic Brain Injury, The New England Journal of Medicine, vol. 26, 2014, 10 pages.
[cited by applicant]
Yousuf et al., Neuroprotection by Progesterone After Transient Cerebral Ischemia in Stroke-prone Spontaneously Hypertensive Rats, Hormones and Behavior, vol. 84, 2016, pp. 29-40.
[cited by applicant]
“Handbook of Pharmaceutical Excipients”, Dimethyl Sulfoxide, 6th Edition, Pharmaceutical Press, 2009, pp. 238-240.
[cited by applicant]
Brooks, et al., “Gas Chromatographic and Mass Spectrometic Studies of Oximes Derived From 20-Oxosteroids”, Steroids, vol. 15, No. 2, 1970, pp. 283-301.
[cited by applicant]
Choudhary, et al., “Pregnenolone Derivatives as Potential Anticancer Agents”, Steroids, vol. 76, 2011, pp. 1554-1559.
[cited by applicant]
Hannay, et al., “Outcome Measures for Patients with Head Injuries: Report of the Outcome Measures Subcommittee”, Journal of Head Trauma Rehabilitation, vol. 11, No. 6, Dec. 1996, pp. 41-50.
[cited by applicant]
Pike, et al., “Effect of Tetrahydroaminoacridine, a Cholinesterase Inhibitor, on Cognitive Performance Following Experimental Brain Injury”, Journal of Neurotrauma, vol. 14, No. 12, 1997, pp. 897-905.
[cited by applicant]
Robel, et al., “Neurosteroids: Biosynthesis and Function”, Critical Reviews in Neurobiology, vol. 9, No. 4, Jan. 1, 1995, pp. 383-394.
[cited by applicant]